iShares Bitcoin Trust vs Regeneron Pharmaceuticals Inc — how do they compare? iShares Bitcoin Trust trades at $46.78 (market cap $68.92B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: iShares Bitcoin Trust and Regeneron Pharmaceuticals Inc are close in size by market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares Bitcoin Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| IBIT | REGN | |
|---|---|---|
Market Cap | $68.92B | $76.40B |
Volume | 46,059,179 | 626,381 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $852.03 |
52-Week Low | $33.29 | $557.73 |
Typical Hold Time | 40 Days | 107 Days |
Enterprise Value | — | $71.12B |
Dividend Yield | — | 0.51% |
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $47.21, down 2.64% on the day, with technical indicators showing a bullish overall signal driven by moving averages. The stock faces immediate support at $46 and resistance at $48. Recent news highlights strong institutional interest with BlackRock's IBIT recording $196 million in daily inflows on October 1, 2026, signaling renewed investor confidence in Bitcoin-focused investment products.
The outlook remains cautiously optimistic given institutional inflows and technical strength, though the absence of traditional financial metrics like P/E and P/S limits fundamental analysis. Key risks include market volatility and regulatory uncertainty, while analyst sentiment appears mixed with technical indicators favoring bullish momentum near-term.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →